CYB005

CYB005

Clinical data
Other names	CYB-005; Deuterated phenethylamine; Deuterated phenethylamine derivative
Drug class	Serotonin receptor agonist; Serotonergic psychedelic[1]

CYB005, or CYB-005, also known as deuterated phenethylamine derivative, is a serotonin receptor agonist and serotonergic psychedelic which is under development for use at non-hallucinogenic doses in the treatment of psychiatric disorders and neuroinflammation.[2][3][1]

Description

It is a phenethylamine derivative and a deuterated compound.[2][3][1] In addition to acting as a serotonin receptor agonist, CYB005 may also inhibit serotonin and dopamine reuptake.[1] The exact chemical structure of CYB005 does not yet seem to have been disclosed.[2][1] However, it appears to be closely related to CYB210010, which itself is non-deuterated.[4][5][6] In addition, CYB005's developer has patent protection for the compound, indicating that its chemical structure has been published in the patent literature.[2][4][7]

As of October 2024, CYB005 is in the research or preclinical stage of development.[2][3] It has been in this developmental stage since at least 2022.[1] The drug is under development by Cybin.[2][3][1] Other related drugs include the deuterated tryptamines CYB003 and CYB004.[1][8]

See also

• List of investigational hallucinogens and entactogens

References

1. Cano GH, Dean J, Abreu SP, Rodríguez AH, Abbasi C, Hinson M, Lucke-Wold B (December 2022). "Key Characteristics and Development of Psychoceuticals: A Review". Int J Mol Sci. 23 (24): 15777. doi:10.3390/ijms232415777. PMC 9779201. PMID 36555419. Table 1. Biochemical structures, mechanisms, and receptor functions of twenty psychoceutical drugs.: [...] Drug Name: Phenethylamine derivative (CYB005): Chemical Structure: *. Target type: –. Method of Action: CYB005 inhibits serotonin and dopamine transporters within the synaptic cleft. [...] These drugs generally bind to CNS G-protein receptors within the 5-HT family, such as 5-HT1A, 5-HT2A, and 5-HT2B, and act agonistically [9,13–15,17,18]. Additionally, two of these, ecstasy and CYB005 (phenethylamine derivative [20]), block the reuptake of serotonin, increasing the serotonin levels within the synaptic cleft [12,21,22]. [...] According to preclinical data, CYB005, a phenethylamine derivative, aims to inhibit serotonin transporters within the synaptic cleft [20–22]. [...] Studies on [...] CYB005 [...] were not found in the literature search, so this information was obtained through the websites of their respective pharmaceutical companies. [...] Table 2. Highlights of the psychoceutical benefits.: Drug: CYB005 (Phenethylamine derivative). Benefit: Treats neuroinflammation and psychiatric conditions. [...] Three [deuterated] drugs that researchers have been working on are [...] CYB005 (for neuroinflammation). [...] Finally, CYB005 is a phenethylamine derivative currently in preclinical development [55], which has the potential to treat neuroinflammation and psychiatric conditions [20]. [...] Of the 20 drugs, [...] CYB005 [...] do not currently have completed clinical trials.
2. "CYB 005". AdisInsight. 28 October 2024. Retrieved 10 November 2024. CYB 005 is a phenethylamine derivative is being developed by Cybin for the treatment of treatment resistant psychiatric disorders.
3. "Delving into the Latest Updates on CYB-005 with Synapse". Synapse. 1 November 2024. Retrieved 10 November 2024.
4. "Cybin Announces Grant of First U.S. Composition of Matter Patent in Support of its CYB005 Phenethylamines Program". Yahoo Finance. 24 October 2024. Retrieved 10 November 2024.
5. Varty GB, Canal CE, Mueller TA, Hartsel JA, Tyagi R, Avery K, Morgan ME, Reichelt AC, Pathare P, Stang E, Palfreyman MG, Nivorozhkin A (April 2024). "Synthesis and Structure-Activity Relationships of 2,5-Dimethoxy-4-Substituted Phenethylamines and the Discovery of CYB210010: A Potent, Orally Bioavailable and Long-Acting Serotonin 5-HT2 Receptor Agonist". J Med Chem. 67 (8): 6144–6188. doi:10.1021/acs.jmedchem.3c01961. PMID 38593423.
6. Palfreyman M, Varty G, Canal C, Hartsel J, Tyagi R, Avery K, Morgan M, Mueller T, Reichelt A, Pathare P, Stang E, Nivorozhkin A (December 2023). "ACNP 62nd Annual Meeting: Poster Abstracts P251 – P500: P405. Discovery and Preclinical Characterization of the Phenylalkylamine, CYB210010, a Potent and Long-Acting Serotonin 5-HT2A Receptor Agonist". Neuropsychopharmacology. 48 (Suppl 1): 211–354 (299–299. doi:10.1038/s41386-023-01756-4. PMC 10729596. PMID 38040810.
7. "Therapeutic phenethylamine compositions and methods of use". Google Patents. 18 August 2021. Retrieved 10 November 2024.
8. Peplow M (June 2024). "Next-generation psychedelics: should new agents skip the trip?". Nat Biotechnol. 42 (6): 827–830. doi:10.1038/s41587-024-02285-1. PMID 38831049.

External links

• Development Pipeline – Cybin